Peptide targeted radiotherapy – a promising new approach to cancer therapy.
Our targeted therapy has been widely validated in clinical studies as well as in routine clinical use in Europe. Learn More
News from Andarix
- Andarix Pharmaceuticals CEO to Present on Building High-Value Biotechnology Companies at Outsourcing in Clinical Trials New England Conference
FOR IMMEDIATE RELEASE October 16, 2025 Contact:Andarix Pharmaceuticals617-957-9858info@andarix.com Presentation Highlights Essential Tools and Strategies for Successful Biotech Company Formation BOSTON, MA – October 16, 2025 – Andarix Pharmaceuticals, a clinical-stage biopharmaceutical company developing next-generation targeted radiotherapeutics for oncology, announced today that Chief Executive Officer Chris Adams will present on the… Read more: Andarix Pharmaceuticals CEO to Present on Building High-Value Biotechnology Companies at Outsourcing in Clinical Trials New England Conference - Andarix Pharmaceuticals Advances Targeted Peptide Therapy Platform for Rare Cancers
CEO to Present at Major Industry Summit as Company Gains Momentum in Personalized Cancer Treatment BOSTON – July 23, 2025 – Andarix Pharmaceuticals, a clinical-stage biotechnology company pioneering targeted peptide therapies for rare cancers, today announced that CEO Chris Adams will present at the 3rd Targeted Radiopharmaceuticals Supply Chain & Manufacturing Summit in… Read more: Andarix Pharmaceuticals Advances Targeted Peptide Therapy Platform for Rare Cancers - Andarix Pharmaceuticals CEO to Present on Targeted Radiometal Therapeutics for Lung Cancer at International Symposium on Bioorganometallic Chemistry 2025
Presentation underscores Andarix’s leadership in advancing radiometal-based cancer therapeutics and highlights partnering and investment opportunities in a rapidly growing field. FOR IMMEDIATE RELEASE August 25, 2025 Contact: Andarix Pharmaceuticals 617-957-9858 info@andarix.com Boston, MA – August 25, 2025 – Andarix Pharmaceuticals, a clinical‑stage biopharmaceutical company developing next‑generation targeted radiotherapeutics for oncology, today… Read more: Andarix Pharmaceuticals CEO to Present on Targeted Radiometal Therapeutics for Lung Cancer at International Symposium on Bioorganometallic Chemistry 2025